{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06521775",
            "orgStudyIdInfo": {
                "id": "24-003306"
            },
            "secondaryIdInfos": [
                {
                    "id": "NCI-2024-05893",
                    "type": "REGISTRY",
                    "domain": "CTRP (Clinical Trial Reporting Program)"
                },
                {
                    "id": "24-003306",
                    "type": "OTHER",
                    "domain": "Mayo Clinic Institutional Review Board"
                }
            ],
            "organization": {
                "fullName": "Mayo Clinic",
                "class": "OTHER"
            },
            "briefTitle": "An Investigational Scan (Ga-68 PSMA-11 PET/CT) for the Detection of Therapy Response in Patients With Metastatic Adenoid Cystic Carcinoma",
            "officialTitle": "Pilot Study Evaluating PSMA PET For Metastatic Adenoid Cystic Carcinoma",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "an-investigational-scan-ga-psma-pet-ct-for-the-detection-of-therapy-response-in-patients-with-metastatic-adenoid-cystic-carcinoma"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "NOT_YET_RECRUITING",
            "startDateStruct": {
                "date": "2024-08-10",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-08-10",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-08-10",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-07-19",
            "studyFirstSubmitQcDate": "2024-07-19",
            "studyFirstPostDateStruct": {
                "date": "2024-07-26",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-19",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-26",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Mayo Clinic",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "This phase II trial tests whether gallium-68 (Ga-68) prostate specific membrane antigen (PSMA)-11 positron emission tomography (PET)/computed tomography (CT) imaging is useful for detecting therapy response in patients with adenoid cystic carcinoma (salivary gland cancer) that has spread from where it first started (primary site) to other places in the body (metastatic). The PET scan detects and takes pictures of where the radioactive imaging agent (68Ga PSMA-11) has gone in the body and the CT scan uses x-rays to create images of the bones and internal organs within the body. Combining a PET scan with a CT scan can help make the images easier to interpret. This study may help researchers learn whether GA-68 PSMA-11 PET/CT is useful for detecting treatment response and guiding treatment decisions in patients with metastatic adenoid cystic carcinoma.",
            "detailedDescription": "PRIMARY OBJECTIVES:\n\nI. Evaluate the feasibility of serial Ga-68 PSMA PET/CT for response assessment in metastatic adenoid cystic carcinoma.\n\nII. Assess the correlation of PSMA PET/CT response assessment with serum extracellular vesical (EV) PSMA levels for patients undergoing treatment for metastatic adenoid cystic carcinoma.\n\nOUTLINE:\n\nPatients receive Ga-68 PSMA-11 intravenously (IV) and then undergo PET/CT 50-70 minutes after injection at baseline and approximately 12-20 weeks during investigational therapy.\n\nAfter completion of study intervention, patients are followed up at 1 day."
        },
        "conditionsModule": {
            "conditions": [
                "Metastatic Adenoid Cystic Carcinoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "DIAGNOSTIC",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 5,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Diagnostic (Ga-68 PSMA-11, PET/CT)",
                    "type": "EXPERIMENTAL",
                    "description": "Patients receive Ga-68 PSMA-11 IV and then undergo PET/CT 50-70 minutes after injection at baseline and approximately 12-20 weeks during investigational therapy.",
                    "interventionNames": [
                        "Procedure: Computed Tomography",
                        "Other: Electronic Health Record Review",
                        "Drug: Ga-68 PSMA-11",
                        "Procedure: Positron Emission Tomography"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "PROCEDURE",
                    "name": "Computed Tomography",
                    "description": "Undergo PET/CT",
                    "armGroupLabels": [
                        "Diagnostic (Ga-68 PSMA-11, PET/CT)"
                    ],
                    "otherNames": [
                        "CAT",
                        "CAT Scan",
                        "Computed Axial Tomography",
                        "Computerized Axial Tomography",
                        "Computerized axial tomography (procedure)",
                        "Computerized Tomography",
                        "Computerized Tomography (CT) scan",
                        "CT",
                        "CT Scan",
                        "tomography"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Electronic Health Record Review",
                    "description": "Ancillary studies",
                    "armGroupLabels": [
                        "Diagnostic (Ga-68 PSMA-11, PET/CT)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Ga-68 PSMA-11",
                    "description": "Given IV",
                    "armGroupLabels": [
                        "Diagnostic (Ga-68 PSMA-11, PET/CT)"
                    ],
                    "otherNames": [
                        "(68)Ga labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC",
                        "(68)Ga-labeled Glu-urea-Lys(Ahx)-HBED-CC",
                        "(68)Ga-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC",
                        "(68)Gallium-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC",
                        "(68Ga)Glu-urea-Lys(Ahx)-HBED-CC",
                        "68Ga-DKFZ-PSMA-11",
                        "68Ga-HBED-CC-PSMA",
                        "68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC",
                        "68Ga-PSMA",
                        "68Ga-PSMA-11",
                        "68Ga-PSMA-HBED-CC",
                        "[68Ga] Prostate-specific Membrane Antigen 11",
                        "[68Ga]GaPSMA-11",
                        "AAA 517",
                        "AAA-517",
                        "AAA517",
                        "Ga PSMA",
                        "Ga-68 labeled DKFZ-PSMA-11",
                        "Ga-68 labeled PSMA-11",
                        "Gallium Ga 68 PSMA-11",
                        "Gallium Ga 68-labeled PSMA-11",
                        "GALLIUM GA-68 GOZETOTIDE",
                        "Gallium-68 PSMA",
                        "Gallium-68 PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC",
                        "GaPSMA",
                        "PSMA-HBED-CC GA-68",
                        "Gallium Ga 68 Gozetotide"
                    ]
                },
                {
                    "type": "PROCEDURE",
                    "name": "Positron Emission Tomography",
                    "description": "Undergo PET/CT",
                    "armGroupLabels": [
                        "Diagnostic (Ga-68 PSMA-11, PET/CT)"
                    ],
                    "otherNames": [
                        "Medical Imaging, Positron Emission Tomography",
                        "PET",
                        "PET Scan",
                        "Positron emission tomography (procedure)",
                        "Positron Emission Tomography Scan",
                        "Positron-Emission Tomography",
                        "proton magnetic resonance spectroscopic imaging",
                        "PT"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Treatment response assessment (Feasibility)",
                    "description": "Data from the prostate specific membrane antigen (PSMA) positron emission tomography (PET)/computerized tomography (CT) exams will be categorized into treatment response categories for each participant using the Response Evaluation Criteria in PSMA PET/CT (RECIP) 1.0 criteria. Tumor volume with PSMA expression on PET/CT will be quantified using MIM Software Version 7.2.7.",
                    "timeFrame": "Up to 20 weeks"
                },
                {
                    "measure": "Response assessment category and percent change in tumor volume",
                    "description": "Will be correlated to percent change in serial PSMA extracellular vesical (EV) from serum measurements from participant data obtained in the MC200708 trial protocol. For continuous measurements (like percent change), scatter plots and simple linear regression will be conducted. Associations of these continuous variables will be done via the Spearman's rank correlation coefficient. For assessment of changes, will use Wilcoxon Signed-Rank test. For any associations of categorical variables, will use the Fisher's Exact test.",
                    "timeFrame": "Up to 20 weeks"
                },
                {
                    "measure": "Incidence of adverse events",
                    "description": "Will be assessed by the number of adverse event incidents reported. Safety will be categorized using the the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.",
                    "timeFrame": "Up to 20 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Percentage change of mean standardized uptake value (SUV) of index lesions",
                    "description": "Will be correlated with percentage change in PSMA EVs.",
                    "timeFrame": "Up to 20 weeks"
                },
                {
                    "measure": "Percentage change of PSMA-avid tumor volume",
                    "description": "Will be assessed on PET correlated with percentage change in PSMA EVs.",
                    "timeFrame": "Up to 20 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* \u2265 18 years of age\n* Diagnosis of metastatic adenoid cystic carcinoma\n* Enrolled in protocol MC200708\n* Ability to tolerate a Ga68 PSMA PET/CT imaging study\n* Willingness to return for a second PSMA PET/CT scan in approximately 12-20 weeks from the baseline PET/CT\n* Ability to give appropriate consent or have an appropriate representative available to do so\n\nExclusion Criteria:\n\n* Unable to undergo PET/CT scan\n* Not a participant in MC200708\n* \\< 18 years of age\n* Persons who are pregnant or nursing\n* Persons unable to consent to the study",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "overallOfficials": [
                {
                    "name": "Brian J. Burkett, M.D., M.P.H.",
                    "affiliation": "Mayo Clinic in Rochester",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Mayo Clinic in Rochester",
                    "city": "Rochester",
                    "state": "Minnesota",
                    "zip": "55905",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Clinical Trials Referral Office",
                            "role": "CONTACT",
                            "phone": "855-776-0015",
                            "email": "mayocliniccancerstudies@mayo.edu"
                        },
                        {
                            "name": "Brian J. Burkett,, M.D., M.PH..",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.02163,
                        "lon": -92.4699
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Mayo Clinic Clinical Trials",
                    "url": "https://www.mayo.edu/research/clinical-trials"
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000003528",
                    "term": "Carcinoma, Adenoid Cystic"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000000230",
                    "term": "Adenocarcinoma"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "asFound": "Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6733",
                    "name": "Carcinoma, Adenoid Cystic",
                    "asFound": "Adenoid Cystic Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M3585",
                    "name": "Adenocarcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "T201",
                    "name": "Adenoid Cystic Carcinoma",
                    "asFound": "Adenoid Cystic Carcinoma",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000004492",
                    "term": "Edetic Acid"
                },
                {
                    "id": "C000718244",
                    "term": "Gallium 68 PSMA-11"
                }
            ],
            "ancestors": [
                {
                    "id": "D000002614",
                    "term": "Chelating Agents"
                },
                {
                    "id": "D000064449",
                    "term": "Sequestering Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000925",
                    "term": "Anticoagulants"
                },
                {
                    "id": "D000065096",
                    "term": "Calcium Chelating Agents"
                },
                {
                    "id": "D000019275",
                    "term": "Radiopharmaceuticals"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M352637",
                    "name": "Gallium 68 PSMA-11",
                    "asFound": "Psychological support",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1804",
                    "name": "Carbamide Peroxide",
                    "relevance": "LOW"
                },
                {
                    "id": "M7662",
                    "name": "Edetic Acid",
                    "asFound": "Everolimus",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7543",
                    "name": "Pentetic Acid",
                    "relevance": "LOW"
                },
                {
                    "id": "M5860",
                    "name": "Chelating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4244",
                    "name": "Anticoagulants",
                    "relevance": "LOW"
                },
                {
                    "id": "M5381",
                    "name": "Calcium",
                    "relevance": "LOW"
                },
                {
                    "id": "M5398",
                    "name": "Calcium, Dietary",
                    "relevance": "LOW"
                },
                {
                    "id": "M21258",
                    "name": "Radiopharmaceuticals",
                    "relevance": "LOW"
                },
                {
                    "id": "T11",
                    "name": "Lysine",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "AnCoag",
                    "name": "Anticoagulants"
                },
                {
                    "abbrev": "BDCA",
                    "name": "Bone Density Conservation Agents"
                },
                {
                    "abbrev": "AA",
                    "name": "Amino Acids"
                }
            ]
        }
    },
    "hasResults": false
}